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Abstract 
Joint replacement is a major orthopaedic procedure used to treat joint osteoarthritis. Aseptic loosening 
and infection are the two most significant causes of prosthetic implant failure. The ideal implant should 
be able to promote osteointegration, deter bacterial adhesion and minimize prosthetic infection. Recent 
developments in material science and cell biology have seen the development of new orthopaedic 
implant coatings to address these issues. Coatings consisting of bioceramics, extracellular matrix 
proteins, biological peptides or growth factors impart bioactivity and biocompatibility to the metallic 
surface of conventional orthopaedic prosthesis that promote bone ingrowth and differentiation of stem 
cells into osteoblasts leading to enhanced osteointegration of the implant. Furthermore, coatings such as 
silver, nitric oxide, antibiotics, antiseptics and antimicrobial peptides with anti-microbial properties have 
also been developed, which show promise in reducing bacterial adhesion and prosthetic infections. This 
review summarizes some of the recent developments in coatings for orthopaedic implants. 
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Abstract: Joint replacement is a major orthopaedic procedure used to treat joint 
osteoarthritis. Aseptic loosening and infection are the two most significant causes of 
prosthetic implant failure. The ideal implant should be able to promote osteointegration, 
deter bacterial adhesion and minimize prosthetic infection. Recent developments in 
material science and cell biology have seen the development of new orthopaedic implant 
coatings to address these issues. Coatings consisting of bioceramics, extracellular matrix 
proteins, biological peptides or growth factors impart bioactivity and biocompatibility to 
the metallic surface of conventional orthopaedic prosthesis that promote bone ingrowth  
and differentiation of stem cells into osteoblasts leading to enhanced osteointegration of 
the implant. Furthermore, coatings such as silver, nitric oxide, antibiotics, antiseptics and 
antimicrobial peptides with anti-microbial properties have also been developed, which 
show promise in reducing bacterial adhesion and prosthetic infections. This review 
summarizes some of the recent developments in coatings for orthopaedic implants.  
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1. Introduction  
Joint arthroplasty (replacement) is a surgical procedure whereby the patient’s joint is replaced by an 
implant. It is one of the most frequently performed procedures for the treatment of end-staged joint 
degeneration (osteoarthritis), which is characterised by pain, loss of joint function and deformity. With 
an aging population, the global burden of disease associated with osteoarthritis is expected to rise, 
increasing future demand for this procedure. Currently, almost 100,000 joint replacements are 
performed in Australia each year, mostly for osteoarthritis. Between 8.3% and 12.1% of these are 
revision arthroplasties performed for implant failure mainly due to aseptic loosening (28%–29%) and 
implant infection (15%–20%) [1]. Aseptic loosening occurs secondary to debris particles arising from 
wear products at the articulating surfaces or from cement disintegration at the cement-bone or cement 
prosthesis interfaces after long periods of repetitive mechanical stress associated with locomotion. 
These wear particles lead to a biologic response characterised by an inflammatory response in  
the immediately adjacent bone that culminates in bone loss and loosening of the implant. The 
incidence of aseptic loosening of joint prosthesis 10 years after surgery is approximately 2% for knee 
and hip replacements [1].  
Where no cement is used (cementless arthroplasty), one of the key determinants of risk of loosening 
without infection (aseptic loosening) is the degree of “osteointegration” of the prosthesis into the bone. 
Osteointegration refers to the process whereby bone grows directly onto or into the implant  
surfaces [2]. Currently, most implants are made of metals such as cobalt chrome alloy, stainless steel 
or titanium alloy. However these metals generally lack a biologically active surface that either 
encourages osteointegration or wards off infection. Attention has thus been focused on developing 
various coatings to supplement the function of current implants [3–10]. The design of these coatings 
must satisfy several important criteria: firstly the coating must be biocompatible and not trigger 
significant immune or foreign-body response; secondly, it must be “osteoconductive” in its promotion 
of osteoblasts (cells that make bone) to adhere to, proliferate and grow on the surface of the implant to 
form a secure bone-implant bonding; thirdly, the implant must also be “osteoinductive” and be able to 
recruit various stem cells from surrounding tissue and circulation and induce differentiation into 
osteogenic cells [2]. Furthermore the coating must have sufficient mechanical stability when under 
physiological stresses associated with locomotion to not detach from the implant surface; Finally,  
the implant coating should have anti-microbial properties minimizing the risk of prosthetic infection. 
Currently none of the commercially available prosthesis are able to satisfy all of the above criteria, 
further emphasizing the need for research and development of new biological coatings for  
orthopaedic implants. 
Convergence and improvements in manufacturing, cell biology and material science have led to 
development of novel biological coatings with osteoconductive as well as osteoinductive properties 
that emulate the natural niche of growing bones. Micro and nano-structured coatings functionalized 
with bioceramics and osteogenic bioactive molecules and drugs have been shown to accelerate 
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osteointegration of implants in various in vitro and in vivo experimental models [3–10]. In addition, 
there has been ongoing research to develop anti-infective surface coatings using silver (Ag+) ions, 
nitric oxide (NO), antibiotics and antimicrobial peptides to inhibit bacterial infection to dissipate the 
risk of prosthetic infection [11–18]. The aim of this review is to discuss recent approaches towards 
improving the integration of orthopaedic prosthesis through novel implant coatings. The first section of 
this review explores recent trends in coatings that promote osteointegration. The effect of coating 
surface topography on osteogenic cells is summarized followed by an outline of the use of various 
calcium phosphate ceramics, extracellular matrix molecules (ECM), bioactive peptides and growth 
factors that are complexed to orthopaedic implants to enhance bony ingrowth. The second part of this 
review summarizes developments in new anti-infective orthopaedic coatings. 
2. Cell Response to Surface Features of Implant Coatings 
In order to design the ideal coating for orthopaedic implants, the response of osteogenic cells to 
micro- and nano-scale architecture surfaces must first be elucidated. Much research has focused on 
examining the effect of surface architecture on osteogenic cell differentiation and adhesion. In the 
following paragraphs the effect of surface roughness, microtopography, nanotopography, porosity and 
surface energy on osteogenic cell function and osteointegration will be examined.  
2.1. Surface Roughness and Microtopography 
Surface roughness affects both osteoblast adhesion and differentiation. Osteoblast-like cells  
grown on rough titanium surfaces (Ra 4–7 µm) show reduced proliferation and enhanced osteogenic 
differentiation with up-regulation of alkaline phosphatase (ALP) activity and the osteogenic differentiation 
marker osteocalcin [19–25]. This differentiation effect of rough surfaces is likely mediated by integrin 
α2β1 with upregulation of a range of osteogenic growth factors including Transforming Growth Factor 1 
(TGF-1), Prostaglandin E2 (PGE2), Wnt pathway agonist Dickkopf-related protein 2 (Dkk 2), Vascular 
Endothelial Growth Factor (VEGF), Epidermal Growth Factor (EGF) and Fibroblast Growth Factor 
(FGF) [25–28]. VEGF is an angiogenic factor while EGF, FGF and TGF-1 are potent mitogenic 
factors for osteoblasts and mesenchymal stem cells [29]. Both Dkk 2 and PGE2 promote differentiation 
of osteoblasts [30,31]. PGE2 is instrumental in roughness-induced cell differentiation. Inhibition of 
PGE2 production by indomethacin blocked expression of osteogenic differentiation markers in cells 
grown on rough surfaces [19,21]. In addition to their effect on osteoblasts, micro-rough surfaces  
(Ra 4–5 µm) also inhibit osteoclast (cells that remove bone) activity by upregulating receptor activator 
of nuclear factor kappa-B ligand (RANKL) and decoy receptor osteoprotegerin (OPG) on osteoblasts. 
Binding of RANKL by OPG prevents it from binding and activating osteoclasts through the RANK 
receptor, thus indirectly promoting net bone deposition [24,32]. Currently, various implants used in 
clinical practice contain surface micro-pits and depressions. The surface features can be engineered 
through techniques such as grit-blasting, acid etching and plasma spraying [33]. These micro-textured 
implants show enhanced osteointegration compared to smooth implants when implanted in vivo into 
bone [34]. 
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2.2. Nanotopography 
Much of the natural environment surrounding osteoblasts and osteoclasts consist of structures with 
nano-scale topography. Collagen fibrils and HA (hydroxyapatite) crystals have lengths ranging from 
50 to 300 nm and width of 0.5–5 nm [33]. As a result, metal surfaces with nano-scale architecture have 
been devised in an attempt to recapitulate the physiological environment of growing bone. Nanoscale 
architecture is defined by feature or grain size less than 100 nm. This architecture affects roughness, 
surface area and surface energy of the material and can thus enhance osteoblast contact signalling. 
Nanophase titanium surfaces with grain size <100 nm, have been shown to be more effective in promoting 
osteoblast adhesion and proliferation compared to microtextured surfaces (grain size > 100 nm) [35–39]. 
Upon adhering to the nanotextured surface, osteoblasts show enhanced cell spreading and filopodial 
extension [37] (Figure 1).  
Figure 1. Bone cells show enhanced spreading and extension of filopodium (white dotted 
ovals) when cultured on nanostructured surfaces. SEM (scanning electron microscopy) 
images of ROS17/2.8 cells grown on nanostructured HA/TiO2 substrates for (a) 3 (b) 6 and 
(c) 9 days. Note the increased cell spreading over time with filopodial extension. Reprinted 
from [35] with permission from Elsevier, Copyright 2014.  
 
The underlying mechanism of the enhanced adhesion is likely related to the increased protein 
adsorption on nanoscale surfaces. Binding of proteins such as vitronectin to the nanophase surface 
induces conformational change on vitronectin exposing more cell binding sites for anchoring 
osteoblasts [38,40–42]. In addition to promoting adhesion, nanotopography can enhance osteogenic 
differentiation in osteoblasts [40,42–44] and affect osteoclast activity. Osteoclast-like cells grown on 
nanophase alumina (grain size < 100 nm) show increased tartrate-resistant acid phosphatase (TRAP) 
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activity and resorption pits on the substrate, indicative of increased bone resorption [45]. The cellular 
response to nanotopography varies according to the level of differentiation of the cell. Undifferentiated 
mesenchymal stem cells do not show osteogenic differentiation in response to nano-scale topography 
while osteoblasts show enhanced differentiation when grown on the same surface [46]. In addition  
to general scale of architecture the way that the various nanoscale structures are arranged on the 
surface can also affect both osteoconduction and osteoinduction. Mesenchymal stem cells grown  
on poly-methyl methacrylate (PMMA) substrates that have semi-ordered nanoscale surface pit 
arrangement show superior differentiation and TGF β1 expression compared to cells grown on 
surfaces with pits organized in perfect hexagonal or square arrays [47] (Figure 2). 
Figure 2. Mesenchymal stem cells (MSC) are sensitive to nanotopography and show 
enhanced osteogenic differentiation when cultured on surfaces with semi-ordered 
architecture. MSCs are cultured on planar PMMA (poly-methyl methacrylate) (a,f,k), 
PMMA surfaces with pits (120-nm-diameter and 100 nm deep) arranged in square arrays 
(300 nm apart) (a,g), PMMA surfaces with pits displaced +/−20 nm from perfect square 
arrangement (c,h), PMMA surfaces with pits displaced by +/−50 nm (d,i,l) and PMMA 
with completely randomly patterned pits. Top row show the nanotopography of the 
different PMMA surfaces. (a–e) Cells co-stained with alizarin-red and antibodies against 
osteopontin (OPN); (f–j) Cells co-stained with alizarin-red and antibodies against 
osteocalcin (OCN); (k–j) Phase contrast microscope image of MSCs grown on planar (k) 
and semi-ordered (J) PMMA surfaces. Note that MSCs grown on pits displaced by 20 and 
50 nm show enhanced osteogenic differentiation and raised OCN and OPN with nodules 
forming in cells on 50 nm displaced surfaces (arrow in d and i). Cells grown on planar 
surfaces and surfaces with pits in ordered array show no osteogenic differentiation and 
maintain fibroblast morphology (a,b,f,j,k). This contrasts with bone nodules forming on 
cells grown on surfaces with pits displaced by 50 nm (arrow) (l). Reprinted from [47] with 
permission from Macmillan Publishers Ltd, copyright 2014.  
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2.3. Porosity 
Surface porosity impacts on osteointegration by allowing direct ingrowth of osteogenic cells into 
the implant, thereby strengthening the bone-implant interface [48]. A number of research groups  
have investigated the effect of pore morphology and dimension on osteoblast differentiation and 
osteointegration. It is generally agreed that scaffolds with interconnected pores show enhanced bony 
ingrowth compared with those with closed pores [46]. This is attributed to improved ingrowth of 
vasculature resulting in better delivery of osteoprogenitors to the scaffold bulk [49]. Furthermore, it 
has been proposed that pores must be sufficiently large for vascular infiltration without compromising 
the mechanical properties of the coating and that an optimal pore size exists. This is supported by 
observations that pore sizes greater than 1mm promote fibrotic tissue ingrowth in preference to bone, 
which is not ideal [48]. Studies along these lines concur that ideal pore size lies within a range between 
100 and 700 µm depending on the morphology of the pores, the composition of the scaffolds and the 
manufacturing technique [50–55].  
2.4. Surface Energy 
Surface energy, also known as surface wettability, enhances both osteoblast adhesion and 
differentiation. Osteoblasts grown on high surface energy (hydrophilic) substrates display increased 
cell adhesion, proliferation and upregulation of various differentiation markers such as osteocalcin, 
type-I-collagen, osteoprotegerin, and glyceraldehyde-3-phosphate-dehydrogenase and raised ALP 
activity [56–58]. This cell adhesion is likely mediated by integrin α5β3 and increased adhesion related 
molecule focal adhesion kinase (FAK) [57,59]. In addition, osteoblasts grown on hydrophilic surfaces 
also secrete osteogenic factors such as PGE2 and TGF β1 [43]. Surface energy has also been shown to 
influence mesenchymal cell differentiation. Hydrophilic surfaces influenced stem cell differentiation 
into osteogenic cells and bolstered bone mineral deposition [60]. The surface energy of metals can be 
improved by incorporating various charged functional groups to the surface with encouraging results 
in both in vitro and in vivo studies [61–63]. These functionalization methods will be discussed in more 
detail later in the section on “metal surface functionalization and ion incorporation”.  
3. Implant Surface Enhancements for Enhanced Osteointegration 
A range of biologically active materials have been studied as potential coatings for orthopaedic 
implants. These can be grouped broadly into calcium phosphate-based bioceramics, metal ion 
incorporated coatings, ECM components and peptides, titanium nanotubes and coatings that act as 
sustained delivery devices for osteogenic growth factors and drugs. 
3.1. Calcium Phosphates 
Calcium phosphates form an integral part of natural apatite bone minerals. Various forms of 
calcium phosphate have been examined as coatings for orthopaedic prostheses. In this group of 
materials, the most thoroughly researched and characterized calcium phosphate is hydroxyapatite 
(HA). Hydroxyapatite is an osteoconductive material that has been shown, in both in vitro and in vivo 
models, to promote osteoblast adhesion and in some studies differentiation [6,64–70]. Furthermore, 
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HA coatings have been studied in a large body of clinical trials in humans [71–81]. Like all other 
calcium phosphates, HA induces a layer of carbonate-hydroxyapatite to form on its surface soon after 
it is implanted in vivo [82–85]. This is a result of an ion exchange process with the environment 
whereby calcium and phosphate ions are released from the implant while proteins from the 
physiological solution are simultaneously deposited onto the HA (Figure 3). The resulting coating 
layer on the HA is known as carbonate-hydroxyapatite (CO-HA) and it resembles the apatite present  
in normal bone [86]. Compared to HA, CO-HA also contains CO3, HPO4, F, Cl, Mg, Na, K ions, and 
some trace elements (such as Sr and Zn) [87]. The new apatite layer acts as a scaffold for osteoblasts 
and is further resorbed by osteoclasts over time and replaced by new bony tissue [84]. One of the main 
drawbacks of HA is its brittle nature and poor mechanical properties [88]. As a result, it is often used 
as a biologically active coating for metal prosthesis.  
Figure 3. Calcium phosphate based ceramics attract natural apatite deposition on its 
surface after immersion in physiological solutions. This occurs through an ion exchange 
reaction between the calcium phosphate in the ceramic coating and the ions and proteins in 
the surrounding solution. SEM images of BCP (bi-phasic calcium phosphates) scaffolds 
before and after immersion in phosphate buffered saline (PBS). (A) HA/TCP scaffolds 
before immersion in PBS; (B) HA/TCP scaffolds after immersion in PBS for 2 weeks. 
Note the deposition of apatite crystals on the scaffold surface. Reprinted from [82] with 
permission from Bentham Open, copyright 2010.  
 
HA-coated implants have been examined in many clinical trials of arthroplasties with disparate 
results. Some studies show improvements in osteointegration of implants coated with HA [71–73,89] 
while other studies fail to show any benefit [74–76,78–81]. The disparity in results likely stems from 
various surgeon and patient factors that often confound clinical trials. One mechanism of failure of 
HA-coated implants revealed by the studies involves delamination and resorption of the HA coating 
due to poor implant-coating attachment [90,91]. Loss of HA coating leads to micromotion of the 
implant and increased fretting and production of debris particles [92]. As a result new techniques of 
coating implants with HA have been developed. These include plasma spraying, thermal spraying, 
sputter coating, pulsed laser deposition, dip coating, sol-gel, electrophoretic deposition, hot isostatic 
pressing and ion-beam assisted deposition [90]. For a detailed review of these techniques the reader is 
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referred to an excellent review by Mohseni et al. [90], but it should be noted that these techniques lead 
to differential surface effects that compound cellular response to the material composition per se. 
Despite inconsistent results in clinical trials, perhaps due to such differential effects, HA coatings have 
delivered improved osteointegration in multiple in vivo animal studies. HA-coated titanium implants 
inserted into the femur of dogs promoted increased bony ingrowth at 6 weeks after surgery compared 
to uncoated titanium implants. This contrasts with the fibrotic tissue that develops between the bone 
and uncoated implants [6,69]. 
The amount of CO-HA that forms on calcium-based bioceramic coatings is determined by the 
amount of soluble calcium phosphate in the coating. Calcium phosphate ceramics exists in many forms 
or “phases”. HA is relatively insoluble calcium ceramic while tri-calcium phosphate (TCP) is a more 
soluble counterpart. Coatings consisting of a combination of HA and TCP are known as bi-phasic 
calcium phosphates (BCP). The TCP in the BCP readily dissolves in the body releasing more ions, 
increasing the amount of carbonatehydroxyapatite that forms on the surface [82,83,93]. BCP 
containing scaffolds are both osteoconductive and osteoinductive, promoting osteogenic differentiation 
of mesenchymal stem cells (MSC) and bone formation in extra-skeletal sites in various animal  
models [7,94–98]. However, one must be cautious before translating these results into human 
applications as there is a high degree of interspecies variability in the capacity of different animals to 
form ectopic ossification in non-skeletal sites [98,99]. More standardization of animal models of 
ectopic ossification is required to clarify and consolidate the existing data from published studies in 
this field. In addition to TCP many other soluble calcium phosphate compounds have also been 
investigated as osteogenic scaffolds including monocalcium phosphate monohydrate (MCPM), 
monocalcium phosphate anhydrous (MCPA or MCP) and dicalcium phosphate dihydrate (DCPD) [93]. 
Amongst these compounds, DCPD, also known as brushite, has been used as a coating on 
commercially available hip and ankle replacement prosthesis with encouraging results in clinical  
trials [100,101]. Brushite is more soluble than TCP potentially allowing for increased apatite formation 
when exposed to physiological fluids [93,102–104]. Furthermore brushite can be deposited more 
homogenously on irregularly shaped prosthesis [105]. Human osteoblasts grown on brushite coatings 
show enhanced differentiation and ECM production compared to non-coated titanium surfaces [106]. 
Titanium implants with brushite coatings enhanced bone ingrowth when implanted into rabbit  
femurs [105]. However more in vivo studies are needed to compare the performance of brushite 
coating with other forms of calcium phosphate coatings.  
The physical morphology and chemical composition of calcium phosphate ceramics can be adjusted 
to maximize osteoinductive potential. Both porosity and the ratio of TCP to HA have been shown to 
affect the amount of bone formed on the scaffolds in extra-skeletal sites [107]. Porous calcium 
phosphates with increased micropores (pores < 10 µm) are more osteoinductive than their non-porous 
counterparts. The optimal pore size must lie within an optimal range between 100 and 500 µm to  
be large enough to allow vascular infiltration and small enough to not impact on mechanical  
properties [54,55,108,109]. The TCP content of BCP also affects osteoinduction. BCPs with higher 
TCP content are more osteoinductive than those with higher HA content [96,110]. TCP likely imparts 
a twofold advantage on bone formation. Firstly, as mentioned earlier, TCP promotes natural apatite 
deposition therefore acting as a bioactive interposing layer between the coating and new bone. 
Secondly, TCP introduces pores to the scaffold as it rapidly dissolves. The content of TCP also 
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influences scaffold performance. When the TCP content is too high, the structural integrity of the 
scaffold is compromised as the excessively porous scaffold collapses, losing its porous architecture in 
the process [110]. Clearly there needs to be a balance between the ability of the implant coating to 
exchange ions with the environment and the maintenance of structural integrity to allow sufficient time 
for bony ingrowth. The exact mechanisms involved in BCP stimulated osteoinduction and the role of 
natural apatite deposition in bone ingrowth is unclear. Both calcium and osteoclast activity have been 
implicated as mediators of calcium phosphate induced osteoinduction [111]. 
3.2. Metal Surface Functionalization and Ion Incorporation 
Unprocessed metal implants usually possess bio-inert hydrophobic surfaces. This can be overcome 
by functionalizing the metal surface with reactive hydroxyl groups (OH) to impart a hydrophilic 
surface. The functionalization process can be accomplished by various techniques such as NaOH 
treatment and submersion in ionic solutions under conditions that are isolated from the  
atmosphere [43,63,112–114]. The functionalized implants generally promote nucleation of natural 
apatite crystals and adsorption of ECM molecules, such as fibronectin, to the implant surface when it is 
submerged in physiological solutions [61,62,115] (Figure 4).  
Metal implants with hydroxylated surfaces promote osteointegration in vivo and bone formation 
when implanted in extra-skeletal sites [43,63,114]. More recently, metals incorporated with calcium, 
phosphorous, magnesium and fluoride ions also show promising results in promoting  
osteointegration [5,116–127]. Like functionalized metallic implants, these ion incorporated surfaces 
also promote deposition of natural apatite through an ion exchange reaction [116]. The osteointegrative 
effects are likely mediated by an increase in osteogenic differentiation of MSC, expression of integrins 
α1, α2, α5, and β1, and upregulated BMP2 (bone morphogenetic protein 2) secretion by  
osteoblasts [117,121,125,128].  
3.3. ECM (Extracellular Matrix Molecules) Components and Biological Peptides 
Various ECM components have shown potential as materials for improving the performance of 
orthopaedic implants. Collagen 1 is one of the most studied materials. Collagen 1 is a major 
component of bone matrix, making up to 80% of the protein in the matrix [129]. Osteoblasts and MSC 
grown on collagen 1-coated metals show enhanced cell adhesion, mediated through an integrin β1 
based pathway [130–132]. Collagen 1 coated metallic implants also promote osteointegration and 
bone-implant apposition in vivo [131,133,134]. The effect of collagen 1 coating can be further 
enhanced by co-immobilization of implants with cartilage ECM molecule sulfated glycosaminoglycan 
chondroitin sulphate [9,135]. 
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Figure 4. Functionalization of Titanium surfaces with hydroxyl (OH−) groups enhanced 
nucleation of bone like apatite on the metal surface when it is submerged in physiological 
solutions. The figure shows transmission electron microscopy (TEM) images and energy 
dispersive X-ray spectrometry (EDX) results of titanium surfaces treated with NaOH and 
heat followed by immersion in physiological solution. (A) Titanium surface before NaOH 
and heat treatment; (B) Titanium surface after NaOH and heat treatment. Note the layer  
of amorphous sodium titanate that forms on the titanium surface; and (C) NaOH and  
heat-treated titanium surface after 72 h immersion in physiological solution. Note the 
deposition of natural apatite on the implant surface. * Center of electron diffraction and 
EDX analysis. Reprinted from [62] with permission from John Wiley & Sons, Inc., 
Copyright 2014. 
 
There are some disadvantages associated with use of ECM molecules. Firstly, most ECM molecules 
are biologically derived and increase the risk of inadvertent introduction of microbes and infectious 
material into the host during implantation. Secondly biologically-derived molecules often suffer from 
significant batch-to-batch variability in quality. To overcome these problems various artificial peptides 
emulating active sequence motifs on the ECM molecules have been developed. One of the most  
well-known peptides is the Arg-Gly-Asp (RGD) peptide. RGD peptide represents sequences on the 
10th type 3 repeat on the main cell binding domain of fibronectin [136], associated with generalised 
cell adhesion. RGD promotes osteoblast adhesion through an integrin α2β1 pathway [132,137,138]. 
Apart from fibronectin, RGD is also the active sequence of matrix molecules OPN, bone sialoprotein 
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(BSP) and vitronectin (VN) that promotes osteoblast adhesion [139]. RGD functions mainly as an 
osteoconductive coating with minimal effects on osteoinduction [140]. RGD-coated titanium implants 
improve implant osteointegration in various animal studies [10,70,141]. The anchoring of RGD to the 
implant surface is an important factor affecting osteointegration. RGD peptides that detach from the 
substrate may inhibit osteoblast adhesion by competing with attached RGD for integrin receptor on 
osteoblasts [142]. Various methods are available to reliably immobilize RGD to implant surfaces, 
including direct physical adsorption and chemical immobilization with a spacer molecule and 
immobilization through an interposing layer of hydroxyapatite [10,143,144]. 
The aspartic acid residue on RGD peptides predisposes it to in vivo degradation. One solution to 
this problem is to cyclize the molecule to form a cyclic RGD peptide. The increased rigidity imparted 
by the ring structure of the cyclic peptide minimizes its degradation [145]. Compared to linear RGD, 
cyclic RGD binds integrins with 20–100 more affinity and shows greater preference for integrins 
αIIbβ3, αVβ3 and ανβ5 [146]. Titanium implants functionalized with Cyclo-(DfKRG) peptide are 
more osteoinductive than those with linear RGD and are more able to stimulate peri-implant bone 
formation in vivo [147–149]. 
RGD peptides only emulate one of many bio-active cell binding domains on fibronectin [150,151]. 
Some of the active motifs on fibronectin can supplement the function of the RGD domain such as the 
proline-histidine-serine-arginine-asparagine (PHSRN) residue. PHSRN is present on the ninth type 3 
repeat on fibronectin [152]. PHSRN bolsters the RGD induced osteoblast spreading and adhesion 
when it is co-presented with the RGD in a specific spatial array [153,154]. The spatial relationship 
between RGD and PHSRN must match the relative positions of the two domains on the fibronectin 
molecule. More recently whole fibronectin fragments (FNIII7-10) containing multiple complementary 
domains of fibronectin have been synthesized to promote cell adhesion [155]. These FNIII7-10 
fragments contain the RGD and PHSRN motifs arranged in the correct spatial relationship. Cells 
grown on FNIII7-10-containing substrates show superior proliferation, adhesion and focal adhesion 
kinase (FAK) activation [155]. Unlike RGD, FNIII7-10 possess a greater specificity for integrin  
α5β1 which is important for differentiation of pre-osteogenic stem cells [155,156]. FNIII7-10  
coated titanium implants promote osteogenic differentiation of MSC in vitro and osteointegration  
in vivo [156]. 
Apart from RGD, other peptides that are evaluated as orthopaedic implant coatings include 
DLTIDDSYWYRI and GFOGER. DLTIDDSYWYRI is an active motif from the large globular 1 
domain of human laminin-2 a2 chain that promotes osteoblast differentiation [157,158]. 
DLTIDDSYWYRI acts through syndecan-1 on the cell membrane resulting in phosphorylation of 
downstream protein kinase C (PKC) delta leading to cell adhesion and enhanced osteointegration of 
implants coated with the peptide in vivo [158,159]. GFOGER is a peptide which resembles sequences 
on the collagen I α1(I) chain. It binds α2β1 integrin and promotes cell adhesion [160]. GFOGER 
coated titanium implants strengthen bone-implant interface bond in vivo [161]. More recent studies 
have combined multiple biological peptides RGD, PHSRN, tyrosine-histidine sequence (YH), and 
glutamic acid-proline-aspartic acid-isoleucine-methionine (EPDIM) into one coating thus effectively 
stimulating multiple signalling pathways to promote osteointegration [162]. 
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3.4. Titanium Nanotubes 
Given the differentiating effects of nanophase architecture on osteoblasts, some researchers have 
used titania nanotubes as a means of creating nanotextured implant coating. Vertically oriented titania 
nanotubes enhance osteoblast differentiation and raise osteocalcin expression and integrin/focal 
contact [163,164]. The behaviour of osteoblasts can be also be regulated by altering the diameter of the 
nanotubes. Osteoblasts grown on nanotubes with diameter of 30 nm showed more proliferation and 
adhesion whereas cells grown on tubes with 100 nm diameter display enhanced differentiation and 
reduced cell proliferation. Smaller diameter vertically aligned nanotubes adsorb more proteins due to 
greater surface area, thus promoting cell proliferation and attachment. In contrast, cells grown on 
larger diameter tubes must extend cell filopodia over larger distances across the lumen to attach to the 
protein adsorbed on the top surface of the tube. This leads to greater strain on the cell with effects on 
cell mechano-transduction thereby enhancing osteogenic differentiation in the process [163]. This 
emphasizes the dichotomy between cell differentiation and cell proliferation, with osteoblasts requiring 
signals from the implant surface to cease proliferation and start differentiation and subsequent bone 
deposition and mineralization. The exact dimensions of nanoscale titania surfaces most conducive to 
osteoblast differentiation is unclear with studies reporting nanotube diameters ranging from 15 to  
100 nm and grain size for nanoscale surfaces ranging from 32 to 56 nm [42,163,164]. Such variation in 
ideal nanotube diameters likely stem from other variables that are not often characterized and 
compared between studies such as the composition of the scaffold and the degree of variations in 
nanotube height. 
More recently, attention has been focused on combining titania nanotube coatings with underlying 
microstructured surfaces to enhance osteogenesis. Addition of titania nanotubes to micro-structured 
titanium further enhances osteoblast differentiation and collagen expression, increasing ALP activity 
and matrix bone matrix mineralization compared to plain microstructured scaffolds [165]. However, 
nanotextured surfaces without underlying microstructure show poor osteointegration. When purely 
nanostructured surfaces are implanted into rat femurs there was an initial period of bony ingrowth 
followed by a general decline in implant fixation strength that coincided with the gradual resumption 
of walking after surgery. Despite the bony ingrowth into the nanoarchitecture, the implant-bone 
interface was too weak and was disrupted by the gross motion of the rat. However, when the same 
implant incorporated underlying microstructure in addition to nanoscale architecture there was further 
improvement in implant fixation strength over standard micro-structured implants. This indicates that 
during initial healing, the micro-structured surface was able to enclose a greater volume of bony tissue 
in its grooves and depressions allowing for stronger immobilization and anchorage, thus allowing  
more time for further bone interdigitation into the nano-scale pores. In such situations the overlying 
nanoscale topography adds to the fixation strength of the underlying microstructured surface [166]. 
3.5. Growth Factors 
During osteogenesis various growth factors are secreted by osteoprogenitor cells and osteoblasts  
to recruit mesenchymal cells and induce osteoblastic-lineage differentiation [29]. Osteogenic growth 
factors such as Fibroblast Growth Factor 2 (FGF2), TGF-β2 and BMP2 have been incorporated into  
to metallic implants as biologic coatings to improve its osteoinductivity [167–170]. TGF-β2 is a 
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chemotactic factor that also promotes proliferation of osteoprogenitor cells and osteoblasts. FGF2 is  
a mitogenic factor for osteoblasts and mesenchymal cells secreted by osteoblasts, macrophages, 
osteoblasts and chondrocytes [171]. BMP2 is secreted by osteoblasts and osteoprogenitors cells to 
promote osteoblastic differentiation of mesenchymal stem cells [171]. Out of these growth factors 
BMP2 is the most commonly used growth factor used to improve osteointegration of metallic 
implants. It is upregulated during the first 3 weeks of osteogenesis [29]. BMP2 and BMP7 are 
approved by the United States food and drug administration (FDA) for treatment of fractures [172]. 
However, in order to achieve optimal results the growth factor must be delivered in a sustained fashion 
that emulates the natural release profile of BMP2 in vivo. Bolus delivery of BMP2 is inferior to 
sustained release of the growth factor in inducing new bone formation in extra-skeletal sites [173]. 
Bolus delivery of BMP2 likely leads to supra-physiological levels of the growth factor that can lead to 
unwanted ectopic ossifications, osteolysis and increased risk of tumorgenesis [174]. In the following 
paragraphs, the various means by which BMP2 can be incorporated into the coating of metallic 
implants will be discussed. Studies that mainly look at sustained delivery of BMP2 without further 
immobilization of the growth factor to metallic substrate will not be covered as they are mainly aimed 
at improving bone regeneration in general and not specifically aimed at implant osteointegration. 
Various techniques are available to incorporate BMP2 into metallic implants (Table 1). A simple 
method is direct adsorption whereby the growth factor is adsorbed to the implant surface through  
non-covalent interaction. However, the main disadvantage of direct adsorption is its low growth  
factor retention time and inconsistent release profile, usually with significant burst release  
characteristics [175,176]. This increases the concentration of the growth factor needed to achieve the 
desired outcome and the chance of toxicity associated with supra-physiological drug levels. Another 
technique is to combine BMP2 to calcium phosphate coatings. The osteoinductive BMP2 combines 
with the osteoconductive calcium phosphate to deliver a multi-functional orthopaedic coating that is 
more effective than plain calcium phosphate coatings [170,177]. The porosity of the calcium 
phosphate is a critical factor that affects the osteoinductivity of BMP2-containing calcium phosphate 
coatings. In rat models of osteoinduction, bone formation is maximal when the pore size of  
BMP2-containing HA scaffolds is within 300–400 µm, this effect is diminished when pore size 
deviates from this value [178,179]. The pore size of calcium phosphate also affects the mode of 
ossification in response to BMP2. HA scaffolds with 300–400 µm pores display predominantly direct 
ossification with no preceding chondral stage while scaffolds with 90–100 µm pores first promote 
cartilage formation followed by enchondral ossification [180]. This likely relates to the reduced 
vascular infiltration owing to reduce pore sizes leading to reduced oxygen levels.  
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Table 1. Various BMP2 (bone morphogenetic protein 2) sustained released mechanisms 
that can be engineered into metallic implants to promote osteoinduction. HA, hydroxyapatite; 
PEM, poly-electrolyte membranes; ECM, extracellular matrix molecules. 
Study BMP2 Sustained Delivery Mechanism Category 
Vehof et al. 2001 [170] calcium phosphate loaded 
Calcium phosphates 
Ono et al. 1995 [177] Calcium phosphate loaded 
Tsuruga et al. 1997 [178] Calcium phosphate loaded 
Kuboki et al. 2001 [180] Calcium phosphate loaded 
Liu et al. 2005 [181] Co-precipitated calcium phosphate 
Kim et al. 2008 [182] 
Poly(D,L-lactide-co-glycolide)  
(PLGA)/nanohydroxyapatite particles 
He et al. 2012 [70] Calcium phosphate/collagen 
ECM and chitosan 
Bae et al. 2012 [183] HA/chondroitin sulfate 
Schützenberger et al. 2012 [184] Collagen sponge 
Geiger et al. 2003 [185] Collagen sponge 
Dawson et al. 2009 [186] Collagen sponge 
Abarrategi et al. 2008  
and 2009 [187,188] 
Chitosan film 
Yang et al. 2012 [189] Heparin-conjugated fibrin 
Heparin conjugation 
Ishibe et al. 2009 [190] Heparin/apatite 
Macdonald et al. 2011 [191] Poly(β-aminoester)/chondroitin sulfate PEM 
Polyelectrolyte 
membrane 
Hu et al. 2012 [192] Gelatin/chitosan PEM 
Shah et al. 2011 [193] Poly(β-amino ester)/polyanion PEM 
Jiang et al. 2012 [194] 
Hyaluronic acid/cationic liposome-DNA 
complex PEM (non-viral transfection) 
non-viral based 
transfection with  
BMP2 gene 
Hu et al. 2009 [195] 
Chitosan (Chi) and plasmid DNA complex PEM  
(viral transfection) 
Qiao et al. 2013 [196] 
PLGA microspheres containing BMP2 cDNA 
plasmid (viral transfection) 
Hu et al. 2012 [197] TiO2 nanotubes Titanium nanotubes 
Lai et al. 2011 [198] TiO2 nanotubes 
More recently there has been a trend to combining BMP2 and calcium phosphate with ECM 
molecules such as collagen and biodegradable polymers into one coating for implants. These new 
modes of growth factor delivery lengthen the release of BMP and showed promising results in 
osteoinduction in various animal models [70,182,183]. Osteoblasts grown on such surfaces also 
display enhanced proliferation and differentiation [183]. The release profile of BMP2 can also be 
improved by incorporation of BMP2 into the 3D lattice structure of HA by co-precipitation of BMP2 
with HA. The BMP2 is gradually released into the cellular environment as HA is degraded extending 
the release time of the growth factor and improving scaffold osteoinductivity [181]. Heparin is another 
molecule that can be added to BMP2 loaded surfaces to improve the effectiveness of BMP2 delivery 
from the implant. BMP2 contains heparin binding sites at its basic-N terminal domain [199]. Binding 
of heparin to BMP2 protects it from degradation and bolsters osteoblast differentiation [200]. Addition 
of heparin to the coating surface maximizes the amount of immobilized BMP2 as well as effectively 
extending growth factor retention time [189,201]. Heparin-conjugated BMP2-containing scaffolds 
Int. J. Mol. Sci. 2014, 15 11892 
 
have been implanted in both skeletal and extra-skeletal sites in animals improving scaffold 
osteoinduction and osteointegration of metallic implants [190,201].  
Incorporating BMP2 and other biological molecules to metallic implants often requires high 
processing temperatures under physiologically detrimental conditions leading to loss of biological 
activity of the complexed molecule. These technical hurdles can be overcome by development of 
layer-by-layer production of poly-electrolyte membranes (PEM). PEM consist of alternative layers of 
cations and anions that are deposited sequentially during production. The layers self-assemble due to 
the electrostatic attraction between the cationic and anionic layers. Various positively and negatively 
charged biomolecules, including BMP2, can be incorporated into the layers of PEM (Figure 5).  
PEM can be formed at room temperature under physiological conditions that do not lead to loss  
of bioactivity of incorporated molecules. It is a versatile and efficient means to controlling the  
physico-chemical properties of the coating surface [202]. Metallic implants with BMP2 containing 
PEM retain bioactivity for 1 year in storage and show sustained release of growth factor in vitro [203]. 
These membranes promote osteoblast differentiation in vitro and ectopic bone formation in vivo when 
implanted in extra-skeletal sites [191]. Polyelectrolyte membranes provide a means of combining 
BMP2 with multiple ECM molecules to produce multi-modal coatings for metallic orthopaedic 
implants. Titanium implants coated with PEM consisting of BMP2, fibronectin, chitosan and gelatin 
promote osteogenic-lineage differentiation of MSCs in vitro and increased bone formation when 
implanted into bone in vivo [192]. PEM technology also allows for co-administration of multiple 
growth factors with different release profiles. PEM films containing BMP2 and angiogenic factor 
VEGF are able to simultaneously release BMP2 over 2 weeks and VEGF over 8 days. The addition of 
VEGF to the PEM-BMP2 enhances osteoinduction in vivo by promoting vascular penetration of the 
scaffold with increased delivery of osteoprogenitors to the bulk of the scaffold leading to greater  
bone deposition [193,204].  
Other recent studies have attempted to load implants with BMP2 DNA plasmids that are able to 
transfect osteocytes resulting in sustained secretion of BMP2 by transfected cells [194–196]. Titanium 
implants coated with BMP2 plasmids promote osteogenic differentiation of both osteoblasts and MSCs 
in vitro compared to non-coated titanium [194,195]. In addition to titanium, BMP2 plasmids can  
also be added to polyethylenimine (PEI) or calcium phosphates [195,196]. To further enhance the 
osteoinductivity, some researchers have managed to pre-transfect osteoblasts with BMP2 and 
angiogenic factor VEGF before they are seeded into CaPO4 scaffolds and implanted intramuscularly  
in vivo leading to enhanced vascularized bone formation [205]. However more research is required on 
the biosafety of BMP2 plasmid before it can be applied to humans.  
Apart from calcium phosphates and PEMs, other BMP2 carriers that are studied include ECM 
molecules, chitosan and titanium nanotubes. ECM contains many binding sites for BMP2. BMP2 
containing ECM constructs show more sustained release of the growth factor compared to other 
substrates such as calcium phosphates [206]. Various ECM molecules are used as carriers of BMP2 
such as collagen and fibrin [184–186,201]. Collagen scaffolds coated with BMP2 enhanced bone 
regeneration [185]. However, studies using collagen-coated metal implants as a means to carry BMP2 
failed to show any benefit in osteoinduction over plain collagen-coated implants [157]. The difference 
in results may be due to technical parameters associated with coating metal surfaces with collagen. 
Chitosan, a polysaccharide extracted from crustaceans has also attracted attention as a possible carrier 
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of BMP2. Chitosan film-based BMP2 delivery constructs are able to promote osteogenesis both  
in vitro and in vivo in animal ectopic ossification models [187,188]. More recently, with advances in 
nanotechnology, titania nanotubes are also employed as reservoirs of BMP2. Titanium oxide 
nanotubes loaded with BMP2 were covered by multilayered coating consisting of alternating 
chitosan/gelatin layers to allow for sustained release of BMP2 [197]. These constructs induced 
osteogenic differentiation of MSC in vitro.  
Figure 5. Schematic diagram showing production process of PEM consisting of layers  
of gelatin (Gel), chitosan (Chi), BMP2 and fibronectin (FN). Titanium alloy Ti6Al4V 
surfaces (TC4) is first coated with gelatin through dopamine (Dop) conjugation. This is 
followed by deposition of chitosan, BMP2 and fibronectin layers. Titanium rods coated 
with these PEM promote osteointegration when inserted into the femur of rabbits. Bottom 
row images show PEM coated titanium rods in the rabbit femur 4 weeks after implantation. 
PEM is a versatile and efficient means of complexing a range of biomolecules to metal 
surfaces. Image adapted from [192] with permission from Elsevier, Copyright 2014. 
 
3.6. Bisphosphonates and Strontium 
As the average life expectancy continues to soar in western societies the number of patients 
diagnosed with osteoporosis is expected to increase. Osteoporosis is a disease characterized by 
progressive loss of bone density and strength and is common in the elderly population. Osteoporosis 
impairs bone remodelling and healing after joint arthroplasties and fracture fixation reducing both 
bone-implant contact and peri-implant bone formation [207–211]. The quality of bone surrounding the 
implant can be improved with systemic bisphosphonate therapy [208]. Bisphosphonates act principally 
through inhibition of osteoclast induced bone resorption thus promoting net bone deposition. However, 
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high doses of bisphosphonate are associated with gastrointestinal upsets, osteonecrosis of the jaw  
and increased fracture risk [212]. The systemic toxicity of bisphosphonates can be minimized by 
immobilization on orthopaedic implant surfaces. The immobilized bisphosphonates rarely diffuse far 
from the implant surface, minimizing the amount of drug entering the circulation and localizing its 
effect at the implant-bone interface [213]. Bisphosphonates can either be attached to implants through 
an interposing layer of calcium phosphate or fibrinogen [3,212,214–217]. The efficacy of different 
bisphosphonates in promoting implant osteointegration also varies. Zoledronic acid-containing 
titanium implants are more effective than Ibandronate or Parmidronate implants in improving  
peri-implant bone density, bone microarchitecture and strength of bone-implant bond in osteoporotic 
rats [212]. The effects of bisphosphonates can be further enhanced by co-immobilization of implants 
with growth factors such as basic fibroblast growth factor (bFGF) leading to improved bone-implant 
integration [214]. The anti-osteoclastic effects of the bisphosphonate combines favourably with the 
osteogenic differentiating effect of bFGF to promote bone remodelling. Apart from bisphosphonates, 
other coatings that show promise in promoting osteointegration of implants in osteoporotic bone 
include collagen, HA and adiponectin [218,219]. 
Bisphosphonate-loaded implants can also improve osteointegration in non-osteoporotic healthy 
bone. Titanium implants with parmidronate improved bone-implant bond in various animal  
models [3,216,220,221]. Bisphosphonate-containing titanium implants have also been tested in human 
patients with fibrinogen-coated titanium dental implants loaded with ibandronate and parmidronate 
improving implant osteointegration at six months after surgery [217]. Another anti-osteoporotic drug 
that is effective as an orthopaedic implant coating is strontium (Sr). Sr promotes osteoclast apoptosis 
through activating calcium sensing receptor (CaR), phospholipase C and NF-κB and osteoprogenitor 
proliferation and differentiation by upregulating Akt and PGE2 and the Wnt/cantenin pathway [4,222]. 
Like bisphosphonates, high systemic doses of strontium can lead to side effects such as  
osteomalacia [223,224]. Localized delivery of Sr through an implant based carrier system minimizes 
systemic toxicity while focusing activity to sites of bone-implant contact. Titanium implants 
containing strontium increase peri-prosthetic bone formation in vivo [225]. To extend the ion release 
time, Sr can be incorporated into the 3D lattice structure of titanium oxide layer on titanium implants 
through hydrothermal treatment. The SrTiO3 layer releases Sr in a sustained fashion and promotes 
osteoblast differentiation in vitro and bone implant apposition in vivo [226]. Titanium nanotubes are 
another means for delivery of Sr in a sustained fashion that can stimulate osteoblastic differentiation  
of MSCs [227]. Sr can also be combined with ECM molecules such as collagen to form composite 
coatings that draw on multiple molecular pathways to drive osteointegration [4]. 
4. Anti-Infection Coatings 
Infection is a main cause of implant loosening after joint arthroplasty. In some cases this 
necessitates removal of the original prosthesis followed by delayed revision procedure to re-implant a 
new prosthesis back into the bone. In such cases, the patient needs to endure periods of immobility and 
accept higher chances of reinfection and loosening associated with the revision procedure. Much 
research has focused on developing orthopaedic coatings with anti-infective properties. However in 
order to create bactericidal surfaces, the mechanism of bacterial colonization of metallic surfaces and 
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the various factors that affect this process must be first elucidated. The environment surrounding 
newly implanted orthopaedic prosthesis predisposes it to infection. Upon implantation, the metallic 
surface of the prosthesis attracts protein adsorption, such as fibronectin, which facilitates bacterial 
adhesion [228]. A foreign body response ensues, blunting the host immune system to combat bacteria. 
Under these conditions the infecting bacteria undergo layered proliferation and secrete a 
polysaccharide-based matrix to create a bacteria-matrix complex, known as a biofilm, that protects the 
bacteria from host immune defenses and anti-microbials [229–231]. Overtime some biofilms can 
slough off the implant and seed into surrounding regions, thus expanding the infectious field [229]. 
Given the difficulty associated with removing established biofilms, much attention has focused on 
creating implant coatings that kill bacteria in the early stages of adhesion, thereby preventing biofilm 
formation. To begin this discussion, the underlying principles of designing anti-infective coatings will 
be first discussed with special emphasis on the response of bacteria to different surface features. This 
is followed by an outline of the different types of anti-bacterial coatings that are being developed. 
4.1. Bacterial Response to Surface Cues 
The complex interaction between the host defense and the invading bacteria during prosthetic 
infections can be briefly summed up by the “race to the surface” theory [232]. This theory states that 
the fate of the implant, in the event of a bacterial infection, depends on the relative speed that bacteria 
and the osteogenic cells attach to the implant surface. If osteoblasts populate the implant surface before 
bacteria, the bacteria will die off and no infection ensues. However if bacteria colonize the implant 
before arrival of osteogenic cells prosthetic infection inevitably follows [232]. Therefore surface 
coatings that preferentially accelerate osteointegration also indirectly reduce the risk of bacterial 
infection. However, in designing implant coatings, one is often faced with dilemma that bacteria and 
host cells possess a very similar repertoire of adhesive mechanisms and respond to similar cues. As a 
result, metallic surfaces that promote osteointegration are also predisposed to bacterial adhesion. This 
is best illustrated by the response of bacteria to various implant surface features. Like osteoblasts, 
bacteria prefer surfaces with higher surface energy (hydrophilic), roughness and nanoscale  
architecture [233–241]. Although most bacteria have hydrophobic surfaces they preferentially bind  
to hydrophilic substrates as these surfaces are more likely to attract protein and natural apatite  
deposition [233,240,241]. Most studies on roughness and bacteria colonization concur that bacteria 
prefer rough substrates with a rise in adhesion when roughness Ra values exceeds a threshold of  
0.2 µm [241]. However, some studies dispute this finding showing no consistent relationship between 
these two parameters [234–236]. This conundrum likely reflects differences in the shape of the 
microarchitecture. Surfaces may have the same roughness Ra value; however this does not account for 
different patterns in surface architecture or feature shapes. The importance of the shape of surface 
features is best demonstrated by one study which showed reduced Staphylcoccus aureus (S. aureus) 
adhesion on poly(dimethyl siloxane) elastomer (PDMSe) substrates with microtopography consisting 
of ribs arranged in a diamond like array like the surface of a fast moving shark compared to smooth 
surface substrates [242]. More recently bacterial adhesion on nanostructured metallic surfaces has been 
examined [239]. S. aureus, Escherichia coli (E. coli) and Pseudomonas aeruginosa (P. aeruginosa) 
show enhanced adhesion and biofilm production when cultured on nanoscale titanium films with  
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100–200 nm scale undulations with 10–15 µm spacing [239]. Nanotopography is more influential  
over bacterial behaviour compared to other surface features such as surface energy and surface  
charge [239]. Given the similar affinity to various surface cues more research needs to be focused on 
developing implant coatings that are able to exploit subtle differences in bacterial and cell response to 
surface topography. 
4.2. Silver Coating 
Various anti-infective agents can be added to the surface of orthopaedic implants to actively kill 
bacteria and prevent infection. Silver (Ag) is a commonly used agent in various anti-infective 
applications. Silver disrupts bacterial membranes and binds to bacterial DNA and to the sulfhydryl 
groups of metabolic enzymes in the bacterial electron transport chain, thus inactivating bacterial 
replication and key metabolic processes [243]. Silver-coated substrates prevent adhesion of S. aureus 
and Staphylcoccus epidermidis in vitro [244]. Silver coatings on megaprosthesis and fracture fixation 
pins reduce the rate of adhesion and infection by S. aureus in vivo [245,246]. Ag-coated fracture 
external fixation pins have also been examined in human studies, however these studies fail to 
demonstrate any advantage in reduction of pin site infections when silver-coated pins are  
used [247,248]. This may be related to the propensity of Ag to be released from the implant which can 
depend on the method used to immobilize Ag on the implant. Like other growth factors, Ag must be 
administered in a sustained fashion to minimize side effects and maximize its anti-microbial activities. 
High Ag levels associated with burst release is toxic to osteogenic cells [249–251]. Various carriers of 
Ag have been developed. Ag can be loaded onto calcium phosphate coatings to impart anti-microbial 
properties to metallic substrates. HA nanocrystals loaded with Ag show anti-microbial activity against 
S. aureus and E. coli in vitro [252]. Similar results are reported by others in vitro [249,253–255].  
In in vivo studies, titanium implants thermal sprayed with HA-containing Ag, reduced methicillin 
resistant S. aureus (MRSA) colonization and adhesion when implanted subcutaneously into rats [11]. 
Other sustained delivery mechanisms of Ag include polyamide, titanium nanotubes, anti-abrasive 
ceramics and polyelectrolyte membranes [250,256,257]. Titanium nanotubes loaded with Ag particles 
are able to provide anti-bacterial activity against S. aureus for 30 days [250]. Polyelectrolyte 
membranes consisting of heparin, chitosan and Ag nanoparticles exhibited anti-bacterial activity 
against E. coli in vitro [257]. Ag can also be incorporated into anti-abrasion ceramics such as titanium 
nitride (TiN) and titanium carbonitride (TiCN) [258–260]. Both TiN and TiCN have been used as 
coatings for hip replacements and impart a low friction coating to orthopaedic implants reducing 
fretting and debris particle formation [261–264]. Addition of Ag to the ceramic film enhanced its 
antibacterial activity [258–260]. However, as the Ag content increased there was also a concomitant 
reduction in corrosion and wear resistance [259,265]. One study reported an optimal Ag density of  
1 × 1018 ions/cm2 which represented a balance between anti-bacterial activity and corrosion  
resistance [265]. However, more studies are needed to verify the efficacy of Ag coatings on 
orthopaedic devices in vivo. Attention must also be focused on examining the mechanical properties of 
Ag coatings on orthopaedic implants given the high loading conditions of joint prosthesis in vivo. 
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4.3. Nitric Oxide 
Nitric oxide (NO) is bactericidal towards both gram positive and negative bacteria and prevents 
bacterial adhesion [266,267]. As a strong oxidant, exposure can lead to oxidation of diverse membrane 
and cytoplasmic proteins. NO reacts with superoxide produced by macrophages to form peroxynitrite. 
Peroxynitrite damages bacterial membranes through peroxidation. This chemical also crosses the 
bacteria membrane to oxidize bacterial DNA, damaging its strands in the process [268]. NO is very 
unstable and is difficult to immobilize resulting in the use of NO donors such as diazeniumdiolates  
and nitrosothiols to produce coatings that release NO for anti-microbial activity [269,270]. 
Diazeniumdiolate has been incorporated into a silicone-based sol-gel derived film and implanted  
into subcutaneous pockets in rats that were infected with S. aureus. The NO-containing implants 
successfully reduced the rate of infection with S. aureus [12].  
4.4. Chitosan 
Chitosan is a polysaccharide derived from crustaceans (animals with hard exoskeletons) that has 
found use as a biocompatible scaffold in a range of tissue engineering applications. Chitosan also 
displays anti-bacterial properties through positive charged amino groups on the chitosan backbone that 
bind to negatively charged bacterial membranes, inducing membrane leakage [271]. Chitosan has been 
incorporated into various polyelectrolyte membranes on metallic implants. PEM with incorporated 
chitosan, heparin and silver nanoparticles shows anti-bacterial activity against E. coli [257,272]. 
However, the anti-bacterial effects of chitosan are limited as the amino groups on chitosan only display 
weak positive charges [273]. Furthermore chitosan is poorly soluble in water with pH of greater than 
6.5 and is very brittle at room temperature [274,275]. As a result, chitosan has been chemically 
modified to address each of these issues. The positive charge of chitosan can be enhanced by addition 
of extra cationic charged groups to its backbone leading to enhancement of bactericidal activity. 
Examples of these derivatives include acyl thiourea and chitosan-N-arginine (CS-N-Arg) [273,276]. 
The water solubility of chitosan can also be improved by addition of fumaric acid or quaternary 
ammonium groups to form O-fumaryl-chitosan and quaternized chitosan respectively [274,277]. The 
mechanical properties of chitosan can be strengthened by blending it with polyethylene glycol 
fumarate [275]. These modifications bolster the antibacterial effects of chitosan [273–276,278]. 
However, more studies are needed to examine the anti-bacterial effects of these chitosan derivatives 
when they are used as coatings on metallic substrates. 
4.5. Titanium Oxide Photocatalysis 
Titanium oxide attains antimicrobial properties after irradiation by UV light. Under UV irradiation, 
titanium oxide reacts with the atmosphere and water to form superoxide and hydroxyl ions. These ions 
react with bacterial membranes causing oxidative damage, leading to derangement of bacterial proteins 
that rely on membrane integrity to function normally [279–281]. This process is known as 
photocatalysis. Thin TiO2 films show anti-bacterial activity against E. coli after UV irradiation [282]. 
Daily irradiation of TiO2 pins with UV light reduced the amount of MRSA colonization when they 
were inserted into rabbit femurs [13]. More recently it was discovered that addition of Ag cations to 
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the titanium oxide can bolster photocatalysis, improving the efficacy of its anti-microbial activity.  
The Ag nanoparticles enhance the antibacterial activity of TiO2 by increasing UV ray absorption  
rather than through Ag ion elution [283,284]. Given the potentially harmful effects associated with  
UV light exposure, other groups have modified TiO2 with carbon (C). Carbon-containing titania is  
anti-microbial against S. aureus, Shigella flexneri and Acinetobacter baumannii upon illumination with 
visible light [280]. However the requirement for implant exposure for UV/light irradiation limits the 
application of these devices in clinical situations. 
4.6. Antibiotic Elution 
Antibiotics have traditionally been incorporated into polymethyl methacrylate (PMMA) cement 
during cemented joint arthroplasties. However, antibiotic-loaded PMMA suffers from several main 
disadvantages. Firstly, PMMA cement loaded with antibiotics shows rapid, unreliable and incomplete 
drug release profiles. Only 20% of gentamicin is released from PMMA cement for the duration of hip 
implant function [285]; Secondly, antibiotics can affect the mechanical properties of the PMMA 
cement accelerating implant loosening. Vancomycin reduces the bending and fatigue strength of 
PMMA cement [286,287]; Thirdly, the heat energy released during setting of PMMA cement  
during arthroplasties limits the choice of antibiotics to those that are heat stable. As a result, much 
research has focused on developing new means of immobilising antibiotics to implants. Biodegradable 
polymers, calcium phosphates and titanium nanotubes are investigated as antibiotic-eluting coatings 
for orthopaedic implants.  
Biodegradable polymers provide a reliable means to deliver antibiotics in a sustained and 
controllable fashion. Polymer microspheres based on polyparadioxanone (PPD), polyglycolic acid 
(PGA), or polylactic acid (PLA) can be successfully loaded with antibiotics and further immobilized  
to metallic substrates [288–290]. Unlike PMMA cements, polymer microspheres are capable of 
completely releasing all antibiotics in a sustained fashion thus minimizing any local or systemic 
toxicity associated with high fluctuating antibiotic concentrations. Gentamicin-loaded poly-L-lactide 
(PLLA) coatings can release 80% of the gentamicin in six weeks thus providing sustained and near 
complete elution of antibiotics [291]. Gentamicin-loaded PDLLA (poly(D,L-lactide)-coated titanium 
implants reduced the risk of osteomyelitis by 90% when implanted into rat tibial medullary canals 
inoculated with S. aureus [14,292]. In addition to antibiotics, antiseptics can also be immobilized to 
polymer coatings on orthopaedic implants. The antiseptics Octenidin and Irgasan reduced the rate of 
osteomyelitis when loaded onto PLLA-coated titanium plates and inserted into rabbit tibias infected 
with S. aureus. These antiseptics are just as effective as antibiotics in reducing bacterial  
infections [291]. The release profile of antimicrobials from polymer carriers can be fine-tuned by 
altering the polymer/solvent/drug ratio. One study found by increasing the PDLLA and reducing  
the gentamicin level the release of gentamicin from PDLLA implant coatings can be prolonged [293]. 
The main disadvantage of antibiotic-eluting polymer coatings is their lack of biologically active 
surfaces. This can potentially be compensated by combination with other biological coatings that  
promote osteointegration. 
Both calcium phosphate and titanium nanotubes have been investigated as possible carriers of 
antibiotics. Stainless steel k-wires coated with gentamicin loaded HA reduced the rate of infections 
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when they are inserted into rabbit tibia, previously inoculated with S. aureus [294]. Calcium 
phosphate-based antibiotic delivery systems show greater anti-microbial activity compared to bone 
cement-based carriers likely due to more complete elution of antibiotics. Vancomycin-coated HA 
beads are more effective than Vancomycin-coated PMMA beads in reducing the rate of osteomyelitis 
when inserted into infected tibias in rabbits [295]. In addition to delivering antibiotics, calcium 
phosphate coatings can also deliver antiseptic agents thus reducing the risk of antibiotic overuse and 
resistance. HA-coated stainless steel pins loaded with chlorhexidine reduce the rate of S. aureus 
infection by 83.3% when implanted into infected goat tibias [15]. Titanium nanotubes have received 
much attention as a carrier of various drugs. Titanium nanotubes can be produced by anodizing 
titanium surfaces to generate nano-tubular surface structures. Titanium nanotubes are capable of 
sequestering antibiotics and delivering them in a sustained, localized fashion. Titania nanotubes loaded 
with gentamicin are effective in reducing the number of colony forming units of S. epidermidis on its 
surface. The antibiotic was fully eluted over 160 min with no impact on the osteoconductive and 
osteoinductive properties of titania nanotubes [296]. The rate of antibiotic elution can be controlled by 
varying the diameter of the nanotubes. Titania nanotubes with diameters of 160 to 200 nm released 
antibiotics at a slower rate compared to smaller nanotubes with diameter of 80–120 nm and were more 
effective than the later in treating S. epidermidis infection in vitro [297]. The elution time of antibiotic 
from titania nanotubes can be further extended by immersing nanotubular metals in physiological 
solutions containing antibiotics that facilitates co-precipitation of natural apatite with the antibiotics 
onto the metal surface. This extended the elution time of penicillin based antibiotics to over 3 weeks [17]. 
4.7. Antimicrobial Tethering 
Antibiotic-eluting implant coatings suffer from several disadvantages. Firstly antibiotic-eluting 
coatings can only release antibiotics at therapeutic concentrations for a limited period of time. As the 
antibiotic is depleted the drug concentration surrounding the implant drops to sub-therapeutic levels 
enabling bacteria that have managed to temporarily evade treatment to re-colonize the implant. 
Secondly, low antibiotic concentrations impose a selectional pressure on the remaining bacteria 
driving the development of resistance to antibiotics in bacteria [229]. In fact, culture of PMMA beads 
loaded with gentamicin extracted during revision procedures on patients with infected orthopaedic 
prosthesis show growth of gentamicin resistant bacteria due to sub-therapeutic gentamicin content [298]. 
Where antibiotic mechanism permits, shortcomings of elution can be solved by tethering antibiotics to 
the implant surface. Tethered anti-microbials will not detach from the implant providing a permanent 
anti-bacterial surface that lasts for the life span of the implant. Various antibiotics with membrane 
disruptive mechanism and antiseptics have been immobilized to metallic implants. For example, 
Vancomycin, which acts on the bacterial cell wall synthesis, covalently linked to titanium implants 
prevents S. aureus colonization and biofilm formation by S. epidermidis in vitro [299,300]. This 
antimicrobial activity is preserved even after 11 months of immersion in PBS [301]. Similar effects 
have been shown in animal studies. Titanium rods with immobilized Vancomycin reduce S. aureus 
colonization and biofilm formation when implanted into infected femoral medullary canals in rats [16]. 
However, tethering is not applicable to antibiotics that target cytoplasmic proteins as they need to 
diffuse from the implant to cross the bacterial membrane.  
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With increasing use of antibiotics in both medicine and industry the incidence of antibiotic 
resistance is rising rapidly, placing greater burden on health systems and driving the search for new 
anti-microbial agents. One type of anti-infective agent that has received renewed attention is the  
anti-microbial peptide. Anti-microbial peptides are sequences of 40–50 amino acid residues that are 
synthesized by mammals, amphibians and plants to combat infection. They are generally hydrophobic 
and cationic containing an abundance of charged amino acids that form amphiphilic α helical 
structures suited to binding to the negatively charged cell membranes of bacteria. Anti-microbial 
peptides generally function by disrupting bacterial membranes [302]. Various anti-microbial peptides 
can be tethered to metallic implants to provide an effective anti-infective coating. Compared to 
antibiotic coatings, anti-microbial peptide coatings enjoy the advantage of heightened bacterial 
specificity with minimal toxicity to host cells. Anti-microbial peptides also reduce the usage of 
antibiotics thus reducing the risk of drug resistance. Titanium substrates immobilized with the 
antimicrobial peptide LL-37, showed bactericidal effects on E. coli [303]. Another antimicrobial 
peptide Magainin I immobilized to gold through a self-assembled thiol-containing monolayer showed 
anti-microbial activity against Listeria ivanovii, Enterococcus faecalis and S. aureus for six months  
in vitro [18,304]. However the main limitation of antibiotic and anti-microbial peptide tethering is a 
lack of antimicrobial impact on bacteria that are not in direct apposition to the implant. This is 
especially relevant in revision arthroplasties where the soft tissue surrounding the bone also contains 
biofilms, which can act as a separate source of infection. Future anti-infective coatings should combine 
both antimicrobial tethering and antibiotic-eluting mechanisms into one coating to provide close as 
well as distant defense against invading bacteria. 
5. Conclusions and Future Directions 
Advances in manufacturing, cell biology and material science have driven the development of new 
biological coatings for orthopaedic implants that aim to recapitulate the natural environment of 
growing bone. Coatings consisting of calcium phosphates, ECM peptides and immobilized growth 
factors exploit the natural cellular mechanisms underlying osteogenesis to promote osteointegration of 
the implant. The design of osteogenic coatings must also account for anti-infective requirements of 
orthopaedic devices. Metallic surfaces fashioned with Ag, NO-generating agents and antibiotics have 
all shown promise in a range of in vitro and in vivo studies in reducing both bacterial adhesion and 
viability. The next step in this field is to combine the various osteogenic and anti-infective coatings 
and draw on the advantages of each class of material to engineer composite structures that can reduce 
the risk of both aseptic and infective loosening in joint arthroplasties. However before this goal can be 
realized, certain barriers need to be overcome. Firstly, more study is required to explore differences 
between cell and bacterial response to various surfaces and materials. Such insight will aid in directing 
the design of scaffolds that are able to exploit these subtle differences in biology to selectively promote 
bone growth while retarding bacterial adhesion. Secondly, standardization is required for experiments 
on osteoinduction and osteoconduction. Due to differences in osteoinductive capacities between 
various animal species a consensus needs to be established in regards to the type of animal model that 
all studies should utilise to simplify inter-study comparisons and data interpretation. The type of 
animal model used should take into consideration differences between human and animal biology and 
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whether findings in animal models regarding osteoinduction can be translated to human subjects. 
Establishing a uniform animal model of osteoinduction would also aid in reducing the variability that 
currently exists with critical experimental results such as ideal dimensions and compositions of 
scaffolds for bony ingrowth.  
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